Beam Therapeutics ( (BEAM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Beam Therapeutics’ stock has experienced a downturn due to mixed signals from its latest earnings report, which showed a decrease in revenue and a significant net loss compared to the previous year. Despite this, some analysts remain optimistic, maintaining a Buy rating and a price target of $80, pointing to potential growth in the biotech sector. However, insider sentiment is negative, highlighted by substantial insider selling, including a notable sale by Fmr Llc, reflecting uncertainty within the company.
More about Beam Therapeutics
YTD Price Performance: 21.01%
Average Trading Volume: 2,640,965
Technical Sentiment Signal: Buy
Current Market Cap: $3.1B
For further insights into BEAM stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.